MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

Research studies explore the different factors that affect health and lead to disease. Clinical trials test the safety and effectiveness of new cancer drugs and treatments. They help us find better ...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF ...

No serious adverse events related to GLSI-100 have been reported to date, highlighting a strong safety profile for the treatment. The Phase IIb clinical trial showed an 80% or greater reduction in ...

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3 No significant safety or dose limiting ...

in the ADPORT-601 Phase 1b clinical trial. This follows a previous pause due to funding concerns. The resumption of enrollment highlights the encouraging safety data observed in earlier cohorts.